MedTrace Logo

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

NCT01046630 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2014-10-13

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.

Conditions

Interventions

DRUG

AZD6765

single infusion

DRUG

Ketamine

single infusion

DRUG

Placebo

single infusion

Sponsors & Collaborators

  • University of Manchester

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Bill Deakin, Prof · University of Manchester, Neurosciance and Psychiatry Unit, UK

  • Guy Goodwin, Prof · University of Oxford, Departmentof Psychiatry, UK

  • Malene Jensen · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046630 on ClinicalTrials.gov